Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

120 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and immunogenicity of the RTS,S/AS02A candidate malaria vaccine in children aged 1-4 in Mozambique.
Macete E, Aponte JJ, Guinovart C, Sacarlal J, Ofori-Anyinam O, Mandomando I, Espasa M, Bevilacqua C, Leach A, Dubois MC, Heppner DG, Tello L, Milman J, Cohen J, Dubovsky F, Tornieporth N, Thompson R, Alonso PL. Macete E, et al. Among authors: heppner dg. Trop Med Int Health. 2007 Jan;12(1):37-46. doi: 10.1111/j.1365-3156.2006.01754.x. Trop Med Int Health. 2007. PMID: 17207146 Free article. Clinical Trial.
Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria.
Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG, Hall T, Krzych U, Delchambre M, Voss G, Dowler MG, Palensky J, Wittes J, Cohen J, Ballou WR; RTS,S Malaria Vaccine Evaluation Group. Kester KE, et al. Among authors: heppner dg. J Infect Dis. 2001 Feb 15;183(4):640-7. doi: 10.1086/318534. Epub 2001 Jan 24. J Infect Dis. 2001. PMID: 11170991 Clinical Trial.
Development and pre-clinical analysis of a Plasmodium falciparum Merozoite Surface Protein-1(42) malaria vaccine.
Angov E, Aufiero BM, Turgeon AM, Van Handenhove M, Ockenhouse CF, Kester KE, Walsh DS, McBride JS, Dubois MC, Cohen J, Haynes JD, Eckels KH, Heppner DG, Ballou WR, Diggs CL, Lyon JA. Angov E, et al. Among authors: heppner dg. Mol Biochem Parasitol. 2003 May;128(2):195-204. doi: 10.1016/s0166-6851(03)00077-x. Mol Biochem Parasitol. 2003. PMID: 12742586
Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A.
Epstein JE, Charoenvit Y, Kester KE, Wang R, Newcomer R, Fitzpatrick S, Richie TL, Tornieporth N, Heppner DG, Ockenhouse C, Majam V, Holland C, Abot E, Ganeshan H, Berzins M, Jones T, Freydberg CN, Ng J, Norman J, Carucci DJ, Cohen J, Hoffman SL. Epstein JE, et al. Among authors: heppner dg. Vaccine. 2004 Apr 16;22(13-14):1592-603. doi: 10.1016/j.vaccine.2004.01.031. Vaccine. 2004. PMID: 15068840 Clinical Trial.
Induction in humans of CD8+ and CD4+ T cell and antibody responses by sequential immunization with malaria DNA and recombinant protein.
Wang R, Epstein J, Charoenvit Y, Baraceros FM, Rahardjo N, Gay T, Banania JG, Chattopadhyay R, de la Vega P, Richie TL, Tornieporth N, Doolan DL, Kester KE, Heppner DG, Norman J, Carucci DJ, Cohen JD, Hoffman SL. Wang R, et al. Among authors: heppner dg. J Immunol. 2004 May 1;172(9):5561-9. doi: 10.4049/jimmunol.172.9.5561. J Immunol. 2004. PMID: 15100299
Update on the clinical development of candidate malaria vaccines.
Ballou WR, Arevalo-Herrera M, Carucci D, Richie TL, Corradin G, Diggs C, Druilhe P, Giersing BK, Saul A, Heppner DG, Kester KE, Lanar DE, Lyon J, Hill AV, Pan W, Cohen JD. Ballou WR, et al. Among authors: heppner dg. Am J Trop Med Hyg. 2004 Aug;71(2 Suppl):239-47. Am J Trop Med Hyg. 2004. PMID: 15331843 Review.
120 results